GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes
GLP-1 RAs may offer substantial cardiorenal and survival benefits in patients aged 80 years and older with T2DM. These findings support the use of GLP-1 RAs as a therapeutic option in this high-risk, older population.
Authors
- Ming‐Hsien Tsai (ORCID: https://orcid.org/0000-0003-3561-4689)
- Mon‐Ting Chen
- Yafang Liu (ORCID: https://orcid.org/0000-0001-8841-0706)
- Yu‐Wei Fang (ORCID: https://orcid.org/0000-0002-1302-1885)
- Jui‐Cheng Chen (ORCID: https://orcid.org/0000-0003-3987-4816)
Institutions
- Fu Jen Catholic University (TW)
- National Taipei University of Nursing and Health Science (TW)
- Ministry of Health and Welfare (TW)
- Shin Kong WHS Memorial Hospital (TW)
- Memorial Hospital (US)
Publication Details
- Journal
- Journal of the American Geriatrics Society
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1111/jgs.70187
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00